Avapritinib FDA approval for advanced systemic mastocytosis
0 Views
administrator
07/09/23
Prithviraj Bose, MBBS, MD Anderson Cancer Center, Houston, TX, speaks on the recent FDA approval of the potent, selective, mutant KIT inhibitor, avapritinib, for the treatment of advanced systemic mastocytosis. Dr Bose shares promising data on the use of avapritinib, highlighting its efficacy profile characterized with a durable response rate of 75%. Approval of avapritinib was based on results of the PATHFINDER (NCT03580655) and EXPLORER (NCT02561988) trials. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
-
Category
Show more
Facebook Comments
No comments found